Lincy S. Lal
University of Texas MD Anderson Cancer Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lincy S. Lal.
Annals of Pharmacotherapy | 2009
Ivy O. Poon; Lincy S. Lal; Marvella E. Ford; Ursula K. Braun
Background: Hypertension and comorbid dementia are common illnesses affecting older adults disproportionally. Medication adherence is vital in achieving therapeutic outcomes. Use of antihypertensive and dementia medications may vary by race/ethnicity and has not been well explored. Objective: To evaluate the utilization of antihypertensive and dementia drugs and adherence in a national cohort of veterans aged 65 years or older with a diagnosis of both hypertension and dementia across different racial/ethnic groups. Methods: This was a retrospective cohort study that used 2 national databases of the Veterans Health Administration to estimate medication utilization and adherence rates among whites, African Americans, and Hispanics from 2000 to 2005. A medication possession ratio of 0.8 or greater defined adherence. The association between race/ethnicity and adherence was analyzed using multivariate logistic regression analysis. Results: A total of 56,561 patients (70.5% white, 15.6% African American, 6.6% Hispanic) aged 65 years or older had diagnoses of dementia and hypertension. African Americans were less likely than whites to receive angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β-blockers, acetylcholinesterase inhibitors, and memantine (p < 0.05). Hispanics were more likely than whites to be prescribed an ACE inhibitor and less likely to be prescribed an ARB, β-blocker, nondihydropyridine calcium-channel blocker (CCB), loop diuretic, β-agonist, or potassium-sparing diuretic (PSD) (p < 0.05). Medication adherence was significantly lower in African Americans than whites in all classes except for ARBs, loop diuretics, and PSDs (p < 0.05). Being Hispanic was associated with significantly lower adherence rates than whites for dihydropyridine CCBs and acetylcholinesterase inhibitors (p <0.05). Conclusions: Racial/ethnic differences exist in antihypertensive and dementia medication use in a cohort of older adults with hypertension and dementia. Adherence rates for a number of antihypertensive and dementia drugs are lower for minorities compared with whites. Healthcare providers should make special efforts to improve medication adherence among minorities.
Journal of Oncology Practice | 2012
Jessica P. Hwang; Michael J. Fisch; Hong Zhang; Michael A. Kallen; Mark Routbort; Lincy S. Lal; John M. Vierling; Maria E. Suarez-Almazor
PURPOSE Patients with hepatitis B virus (HBV) infection are at risk for reactivation after chemotherapy. Effective prophylaxis is available but depends on detection of prior infection. Previous studies have shown low screening rates, but no large-scale US studies have been conducted. We sought to determine predictors of screening and positive HBV test results in patients receiving chemotherapy. METHODS We conducted a retrospective cohort study of patients with newly diagnosed cancer who received chemotherapy between January 2004 and September 2007 at a comprehensive cancer center. We determined rates and predictors of screening for HBV infection with HB surface antigen (HBsAg) and antibody to hepatitis B core antigen (anti-HBc) tests as well as the prevalence and predictors of positive results. We explored rates of acutely elevated liver function tests and liver decompensation after chemotherapy. RESULTS Of 10,729 new patients who received chemotherapy, 1,787 (16.7%) underwent HBsAg or anti-HBc screening. Less than 20% of patients with HBV risk factors were screened, even though their odds of HBV infection were increased four-fold compared with those without risk factors. The prevalence of chronic HBV infection was 1.5%. whereas 7.4% had positive anti-HBc only. The strongest predictors of HBV screening were having a history of HBV infection, hematologic malignancy, and rituximab treatment (P < .001). Asian ethnicity was not a significant predictor of screening, despite being a strong and highly significant predictor of positive test results (P < .001). CONCLUSION HBV screening among patients with cancer is low, especially among those known to be at high risk for HBV infection. Future research directed toward identifying best screening methods and HBV risk tools will be necessary to reduce the risk of reactivation of HBV infection after chemotherapy.
American Journal of Clinical Oncology | 2012
Lincy S. Lal; Stacey Dacosta Byfield; Eric L. Chang; Luisa Franzini; Lesley Ann Miller; Rebecca Arbuckle; Liezl Reasonda; Chun Feng; Andrea Adamus; John Michael Swint
BackgroundIn this study, we compare 2 treatment options and determine cost-effectiveness and cost-utility. MethodsWe carried out a decision analysis populated with data from patients with brain metastasis in a concurrent trial randomized to either stereotactic radiosurgery (SRS) and observation or SRS and whole brain radiation therapy. Outcomes included actual life years saved (LYS), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). Costs used were from the healthcare perspective and utilities were captured through a time-trade-off method, using 10-year, 5-year, and 1-year time horizons. One-way sensitivity analyses were carried out to determine robustness of the decision analysis model. ResultsCompared with SRS and whole brain radiation therapy, SRS and observation not only had a higher average cost (
BJUI | 2011
Eric Jonasch; Lincy S. Lal; Bradley J. Atkinson; Stacey Dacosta Byfield; Lesley Ann Miller; Lance C. Pagliaro; Chun Feng; Nizar M. Tannir
74,000 vs
Oncologist | 2010
Saroj Vadhan-Raj; Xiao Zhou; Kurt C. Sizer; Lincy S. Lal; Xuemei Wang; Joyce Roquemore; Weiming Shi; Robert S. Benjamin; Benjamin Lichtiger
119,000, respectively) but also a higher average effectiveness (0.60 LYS vs 1.64 LYS, respectively) with an ICER of
Community oncology | 2011
Tisha M. Felder; Lincy S. Lal; Charles L. Bennett; Frank Hung; Luisa Franzini
44,231/LYS or
Hospital Pharmacy | 2015
Laura Challen; Sylvester Agbahiwe; Tara Cantieri; Jessica Garcia Olivetti; Theophilus Mbah; Yvonne Mendoza-Becerra; Cesar Munoz; Michelle Nguyen; Katashia Partee; Lincy S. Lal; Jocelyn Thomas; Monica Green
41,783/QALY (with utilities captured using a 10-year horizon). Slightly higher ICER estimates were achieved with utilities captured using the other time horizons (
Journal of Oncology Pharmacy Practice | 2011
Lincy S. Lal; Frank Hung; Chun Feng; Amy Zhuang; Stacey Dacosta Byfield; Lesley-Ann Miller; Andrea Adamus; Rebecca Arbuckle
43,280/QALY and
Hospital Pharmacy | 2011
Brian M. Dee; Jeffrey J. Bruno; Lincy S. Lal; Todd Canada
44,064/QALY, respectively). Sensitivity analysis showed that the following variables had the highest impact on the ICER: probability of no recurrence in recursive-partitioning analysis class 2 after SRS and observation; probability of being alive after SRS and observation in recursive-partitioning analysis class 2 and being treated for recurrence. ConclusionsCompared with other interventions in the
Social Work in Public Health | 2009
Pauline Vaillancourt Rosenau; Lincy S. Lal; Jay H. Glasser
50,000 to